Amgen's Drug Combination Boosts Lung Cancer Survival by 58%
A new drug combination from Amgen has shown promising results in improving the survival rates of patients with a particularly aggressive form of lung cancer. The treatment, which includes Amgen's drug alongside AstraZeneca's immunotherapy, has been found to reduce the risk of death by 58% for these patients.
The groundbreaking discovery was made during a clinical trial involving over 500 patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The study revealed that the drug combination significantly prolonged the lives of those suffering from this aggressive form of lung cancer.
Dr. Sean Harper, Executive Vice President of Research and Development at Amgen, highlighted the significance of the findings:
"We are excited about these data, which show a meaningful improvement in survival for patients with locally advanced or metastatic non-squamous NSCLC, a particularly challenging subgroup of patients."
The trial results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The findings will now be submitted for review by regulatory authorities, potentially paving the way for a new treatment option for patients with this aggressive form of lung cancer.
The combination therapy is believed to work by enhancing the effectiveness of the immune system in attacking cancer cells. The study showed that the treatment led to a median survival of 18.6 months, demonstrating a significant improvement compared to the current standard of care.
AstraZeneca's Chief Medical Officer, David Chen, expressed optimism about the potential impact of the findings:
"These results are promising, and we look forward to working with our partners at Amgen to bring this potential new treatment option to patients who need it the most."
The clinical trial results showcase the power of combining different drugs to tackle cancer more effectively. As the treatment proceeds through the regulatory review process, patients with locally advanced or metastatic non-squamous NSCLC may soon have a new treatment option to extend their lives.
Improved Survival Rates for Patients with Aggressive Lung Cancer
A new drug combination from Amgen and AstraZeneca has demonstrated a significant improvement in survival rates for patients suffering from locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The treatment, comprised of Amgen's drug and AstraZeneca's immunotherapy, has shown a 58% reduction in the risk of death among patients.
The findings were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The median survival time for patients receiving the combination therapy was 18.6 months, surpassing the current standard of care.
The success of combining drugs highlights the potential for improved cancer treatment outcomes. As the treatment progresses through the regulatory review process, patients with locally advanced or metastatic non-squamous NSCLC may soon have a new option to extend their lives.
New Treatment Option for Patients with Aggressive Lung Cancer
A promising treatment option has emerged for patients suffering from locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The combination of Amgen's drug and AstraZeneca's immunotherapy has shown a reduction of 58% in the risk of death among patients.
The findings were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, where researchers discovered a median survival time of 18.6 months for those receiving the combined treatment, surpassing the current standard of care.
The success of combining drugs highlights the potential for improved cancer treatment outcomes. As the treatment continues through the regulatory review process, patients with locally advanced or metastatic non-squamous NSCLC may soon have an additional option to prolong their lives.
<small>Source: CNBC — read the original story there.</small>